Resources

×

Spotlight Resources

Infographics

Why MMIT’s Lab Data?

Open to learn why MMIT’s Lab Data is the best solution for longitudinal tracking of patients.

Market Access Downloads

Psoriasis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Infographics

How to Stop Losing Money Due to Inefficient Formulary Verification

Contracting in pharma has grown increasingly complex, which results in significant rebate leakage for manufacturers. Recent MMIT research highlights the severity of the problem.

Case Studies

MMIT’s Strategic Partnership: Rapid Response In Action

How MMIT’s longstanding advisory relationship with a global pharmaceutical company helped transform its portfolio strategy.

Case Studies

From Impasse to Insights: Finding a Way Forward With FormTrak

Learn how pharma companies that were early adopters of MMIT’s FormTrak integration in Veeva CRM see the new functionality changing their workflow.

Playbooks

Patient Support Programs

Patient assistance programs can have an enormous impact on the time-to-treatment for prescribers and patients. Your ability to establish a patient assistance program strategy, especially when there are barriers to prescribing.

Messaging Playbooks

Monitor Payer Messaging Perception: Breast Cancer

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in breast cancer.

Webinars

Meet the Expert: Addressing Rebate Leakage Through Industry-Leading Data & Workflow Automation

Learn the causes of rebate leakage and how MMIT’s Contract Validation solution can provide a workflow automation platform that enables manufacturers to validate formulary positioning at scale.

Messaging Playbooks

Monitor Payer Messaging Perception: Migraine

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in migraine.

Videos

RC Claim Assist for Pharma Manufacturers

Messaging Playbooks

Monitor Payer Messaging Perception: Rheumatoid Arthritis

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in rheumatoid arthritis.

Videos

30-40% of Medical Drug Claims Submitted Have An Error

Messaging Playbooks

Monitor Payer Messaging Perception: Oncology Biosimilars

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in oncology biosimilars.

Indication Brief Excerpts

Metastatic Melanoma

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Messaging Playbooks

Monitor Payer Messaging Perception: Atopic Dermatitis

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in atopic dermatitis.

Messaging Playbooks

Monitor Payer Messaging Perception: Non-Small Cell Lung Cancer

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in non-small cell lung cancer.

White Papers

Patient Access During Pre-Launch Phases

Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.

White Papers

Insurer, Specialty Pharmacy Rely on Solutions from RJ Health to Price Drugs Correctly

As specialty pharmaceuticals consume an ever-larger share of healthcare benefit dollars, payers, providers and other healthcare organizations are realizing the importance of managing drugs administered under the medical benefit, which most often are specialty drugs.

Case Studies

A Second-to-Market Success

Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.

Case Studies

Helping MarketLauncher Capture Success

Learn how MMIT and MarketLauncher helped a medtech company engage a difficult-to-reach health plan audience.

Case Studies

Analytics Data Helps Healthcare Services Company Complete the Picture for Providers

Learn how a healthcare services company partnered with MMIT to help support its provider network with coverage data.

Case Studies

Value Proposition Message Testing

Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers.

Case Studies

Strategic Launch Report With In-Depth Interviews

Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.

Case Studies

Post-Launch Tracking Surveys

Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market.

Case Studies

Drug Launch Planning: Using Analytics to Overcome Market Access Challenges

Learn how a small pharma company leveraged MMIT’s Analytics platform to drive its messaging with healthcare providers as it launched its first commercial product at the start of the COVID-19 pandemic.

Case Studies

Understanding PBM Competitive Intelligence

Take a look into how a PBM was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Case Studies

Streamlining the Referral Process

Take a look into how a specialty pharmacy partnered with MMIT to enhance its referral process and decrease time to therapy for patients.

Case Studies

Prepare For a Device Launch

Learn how a medical device company partnered with and leveraged MMIT’s Payer Landscape data.

Case Studies

Custom Pricing and Contracting Studies

Learn how a pharma company’s market access team leveraged MMIT’s quantitative online surveys to obtain a custom pricing and contracting study to support its drug launch.

Case Studies

Advisory Board Meetings

Learn how a pharma company leveraged MMIT’s advisory board service to get unique insights from payers and physician key opinion leaders (KOLs) to support its drug launch.

Case Studies

Systematizing Health Plan Targeting

Learn how a healthcare IT organization automated payer account identification and outreach.

Case Studies

Breaking Down Granular Enrollment Data

Learn how a healthcare IT organization was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Webinars

Meet the Expert: Pathways Utilization Amidst Rising Costs of Oncology Treatments

Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.

Webinars

Meet the Expert: Understanding the Impact of Humira Biosimilars on Market Access

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

Webinars

Meet the Expert: Access Trends for Innovative Technology Cell and Gene Therapies, Biomarkers, and Telemedicine

Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.

Webinars

Meet the Expert: Predicting Payer Uptake with Precision

Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.

Webinars

Meet the Expert: Medical Reimbursement/Billing Challenges Faced by the Market Are Only Growing

Learn how claims reimbursement is currently being managed, as well as some best practices for leveraging specialty drug data to streamline the process.

Webinars

Meet the Expert: Advances in Formulary Management: Integrated Solutions to Optimize Management of Medical and Pharmacy Benefit Drugs

Learn how formularies are currently managed, examine some of the key challenges faced by payers and PBMs, and evaluate new integrated solutions to optimize management of both pharmacy and medically covered drugs.

Webinars

Meet the Expert: Tracking Access in Real-Time

Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards and real-time alerts.

Webinars

Meet the Expert: Navigating the Complex U.S. Payer Landscape to Grow Your Business

Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and marketing team is crucial.

P&T Sessions

Ulcerative Colitis

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

Immunology Biosimilars: Webcast

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

Atopic Dermatitis

MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

Heart Failure

MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Sessions

Non-Small Cell Lung Cancer

Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Neutropenia

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

Market Access Downloads

Atopic Dermatitis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Multiple Sclerosis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Rheumatoid Arthritis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Ulcerative Colitis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Multiple Myeloma

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Crohn’s Disease

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Diabetes

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Prostate Cancer

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Acute Myeloid Leukemia

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Non-Small Cell Lung Cancer

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Infographics

NDC Mandate Management

RJ Health, an MMIT company, conducted a survey on NDC mandates. In 2016 and 2021, we asked payers questions such as how they are managing NDCs and who performs unit conversions. We compiled these results

Infographics

Analyzing the Patient Journey

Learn how Patient Access Analytics from MMIT and Panalgo can show how coverage decisions influence physician prescriber behavior.

Indication Brief Excerpts

Non-Small Cell Lung Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Bladder Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Breast Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Orphan Diseases

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Multiple Sclerosis

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Rheumatoid Arthritis

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Colorectal Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Multiple Myeloma

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Prostate Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Diabetes

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

CAR-T

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Atopic Dermatitis

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Migraine

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Product Brochures

Clinical Lab Data

Inform site selection, drive trial awareness and enrollment, and uncover patient-centric signals for evidence generation and outcomes studies.

Product Brochures

Bridging as a Service

Learn more about MMIT’s Bridging as a Service solution.

Product Brochures

Surveillance

Learn more about MMIT’s Surveillance solution.

Product Brochures

PULSE Pathways Analytics

PULSE Pathways includes data on third parties that develop pathways for IDNs and payers.

Product Brochures

PULSE Provider Analytics

PULSE Provider includes clinical pathway information for IDNs that create and maintain their own pathways.

Product Brochures

Patient Access Analytics

Read a summary of the Patient Access Analytics solution from MMIT and Panalgo.

Product Brochures

Commercial Lab Data

Learn more about MMIT’s proactive, economic, precise, and comprehensive solution that can help manufacturers promote their therapies to specific providers using lab test results before a diagnosis and/or prescribing decision is made.

Product Brochures

FormTrak & Veeva

Learn more about MMIT’s FormTrak integration with Veeva CRM.

Product Brochures

Contract Validation

Contract Validation is a workflow automation platform that enables manufacturers to validate formulary positioning at scale by crosschecking the contract language against MMIT’s industry-leading data.

Product Brochures

Navigator

Learn more about MMIT’s Formulary Navigator solution.

Case Studies

Credibility’s Competitive Advantage

Learn how RJ Health helped a niche healthcare company bolster its payer communications.

Informational

Tips to Engage Pharma Manufacturers

Without the right tools, your account managers will face many obstacles trying to win more pharma business. We’ll give you our top tips on how to engage with pharma manufacturers and differentiate your organization.

Informational

How Will MMIT’s FormTrak Integration in Veeva CRM Change Your Workflow?

MMIT’s new FormTrak integration in Veeva CRM changes how pharma companies detail healthcare providers. Now your field teams can access FormTrak seamlessly within Veeva thanks to the first native market access integration.

Infographics

Payer Profile Sample: State

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Infographics

Payer Profile Sample: PBM

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Infographics

Payer Profile Sample: Payer

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Infographics

Payer Intelligence Toolkit

You need a variety of resources to develop a successful payer strategy. Download our infographic to learn how MMIT can help your organization.

P&T Sessions

How Will The Complexity Of The Ulcerative Colitis Contracting Category Affect The Review Of New Entrants?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Does The Impending Launch Of Several New Biosimilars For Humira Impact Formulary Coverage and Market Access?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

As New Entrants Prepare To Enter The Ulcerative Colitis Market, Which Agents Will Be Disadvantaged?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Will The Existence Of Medical And Pharmacy Benefits In The Market Basket For Ulcerative Colitis Affect Formulary Strategy?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Will Portfolio Contracting Impact The Number Of Adalimumab Products With Parity Access On Formulary?

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

Could Manufacturers Entice Payers to Make Adalimumab Coverage Decisions?

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Do Payers See The Adalimumab Biosimilar Story Playing Out In 2023?

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Will Existing Contracts With AbbVie Shape Payer Strategy Towards Shifting Market Share To Biosimilars?

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How will contracting impact formulary placement of treatments for atopic dermatitis?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

How does the launch of several new treatments for atopic dermatitis impact formulary coverage and market access?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

How do the dermatologist perceive the efficacy data of new approvals in atopic dermatitis?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

How does the P&T committee anticipate new approvals will impact the atopic dermatitis treatment paradigm?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

How will the JAK inhibitor class-wide black box warning affect perceptions of Opzelura for atopic dermatitis?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Sessions

What is a Cardiologist’s Perspective On the SGLT2i Class in Heart Failure?

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Sessions

Are the Heart Failure Benefits of the SGLT2 Inhibitors Seen As a Class Effect?

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Sessions

Is Entresto at Risk From Jardiance and Farxiga in Heart Failure?

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Sessions

Would Payers be Willing to Prefer Steglaro to Provide a More Affordable Medicare Option?

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Sessions

Question posed by non-Oncologist P&T member: “Are mutations in oncology mutually exclusive”?

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Oncologist’s opinion on the drugs for review capmatinib, tepotinib, crizotinib, and cabozantinib.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Introduction into scenario 1 pricing

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Is there a product that would better suit a particular MET Exon 14 Skipping Mutations NSCLC patient?

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Oncologist reactions to Rolontis®. Is it best suited to certain patients?

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Does Neulasta® Onpro® retain any advantages as the only on-body injector? (Oncologist)

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

What shifts have been observed by Oncologists in the treatment of Neutropenia? (Oncologist 2)

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Financial considerations for Rolontis® (Contracting Pharmacist)

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

Videos

Unlock the Power of Account Intelligence

View a demo of the Payer Landscape tool.

Videos

Healthcare Frustrations

Understanding and maintaining insight into payer enrollment is difficult. At MMIT, we are focused on helping our clients understand the complex payer landscape.

Videos

MMIT’s Integration in Veeva CRM: Pre-Call Planning

Learn more about how MMIT’s FormTrak solution can help your team.

Videos

MMIT’s Integration in Veeva CRM: Card Creation

Learn more about how MMIT’s FormTrak solution can help your team.

Videos

MMIT’s Integration in Veeva CRM: Triggered Email

Learn more about how MMIT’s FormTrak solution can help your team.

Videos

MMIT Executive Viewpoint: Chris Webb

How Medical Billing and Coding Can Impact Patient Access. Hear from the experts from RJ Health, an MMIT company.

Webinars

Meet the Expert: Predicting Enrollment Changes in the COVID Era

Factors complicate the payer enrollment landscape, making it challenging to project membership rolls across payers, geographies and channels. See enrollment projections, the drivers behind them and what you can expect from the 2021 payer landscape.

Webinars

Meet the Expert: MMIT’s FormTrak Integration in Veeva CRM: Smoothing Access to Therapy

MMIT’s FormTrak tool helps prescribers get their patients on the right therapy even amid complex drug coverage requirements. FormTrak’s integration in Veeva CRM, pharma field teams can deliver an access message right in Veeva’s platform.

Title

Description